Hyderabad startup Acubiosys commercializes AI-driven skin and wound care products

Hyderabad-based biotechnology startup Acubiosys Private Limited has successfully developed and commercialized two patented, AI-driven healthcare products at the CDFD Technology Incubator. The new formulations utilize nanotechnology to treat chronic skin disorders and promote wound healing.

The startup, which is incubated at the business incubator of the BRIC-Centre for DNA Fingerprinting and Diagnostics (BRIC-CDFD) in Hyderabad, focused on creating evidence-based natural and synthetic therapeutics. These therapies target conditions such as psoriasis, atopic dermatitis, and diabetic foot ulcers.

The first product, named BOCUGL, is a patented topical formulation designed for the management of psoriasis, atopic dermatitis, and melasma. The second product, AZBECO, is a patented advanced wound care formulation developed to promote faster healing of chronic wounds and diabetic foot ulcers. Both products were manufactured in India under AYUSH regulatory compliance and Good Manufacturing Practices standards.

According to the company, the underlying technologies and formulations have been submitted for patent applications in India, China, and the United States to protect its global intellectual property.

Dr. Srinivas Maddi, Founder and CEO of Acubiosys Private Limited, stated that the incubator's facilities were crucial to their development process. He noted that leveraging the research and development facilities at the CDFD Technology Incubator allowed the company to undertake critical preclinical studies, including animal studies, which enabled the validation and advancement of their technology.

The incubator also provided the startup with access to laboratory infrastructure, mentorship, industry and investor networking, regulatory support, and strategic guidance throughout its commercialization journey.

Looking ahead, Acubiosys plans to expand its research pipeline through AI-driven therapeutic discovery platforms. These platforms will integrate computational biology, biomarker analysis, and experimental validation to identify next-generation phytopharmaceuticals and precision medicine candidates for autoimmune and infectious diseases.